Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics


Hoth Therapeutics, Inc. (HOTH): $1.26

0.01 (+0.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HOTH Stock Price Chart Interactive Chart >

Price chart for HOTH

HOTH Price/Volume Stats

Current price $1.26 52-week high $3.50
Prev. close $1.25 52-week low $1.14
Day low $1.23 Volume 75,644
Day high $1.27 Avg. volume 2,321,501
50-day MA $1.32 Dividend yield N/A
200-day MA $1.73 Market Cap 30.08M

Hoth Therapeutics, Inc. (HOTH) Company Bio


Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.


HOTH Latest News Stream


Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream


Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

Yahoo | September 8, 2021

EXCLUSIVE: Hoth Reports Safety Data From Early-Stage Study Of BioLexa Platform In Eczema

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma engaged in the development of therapies for unmet need, releases positive early-stage data for its BioLexa platform. What Happened: New York-based Hoth says data from the Cohort 1 of a two-part, Phase 1b study of BioLexa showed no serious adverse events and no drug-related treatment-emergent adverse events. BioLexa is Hoth's proprietary antimicrobial topical formulation being developed for the treatment of diseases mediated by St

Yahoo | September 8, 2021

Thinking about buying stock in CohBar, Mogo, BioCryst Pharmaceuticals, Hoth Therapeutics, or Maravai Lifesciences?

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CWBR, MOGO, BCRX, HOTH, and MRVI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.

PR Newswire | August 11, 2021

Hoth Therapeutics'' mRNA ''Frameshifting'' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast

PR Newswire | August 11, 2021

Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

Yahoo | August 11, 2021

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo 8.62%
3-mo -18.18%
6-mo -42.99%
1-year -46.15%
3-year N/A
5-year N/A
YTD -46.84%
2020 -61.71%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7908 seconds.